• About
  • Is there a medical test that can detect the health of gut flora?

TK Talk

~ Demystify science, Kant not cant

TK Talk

Tag Archives: Vedolizumab

What is the current state of the HIV cure?

04 Thursday May 2017

Posted by Tirumalai Kamala in Anti-viral, CD4 helper T cells, CD8 T cells, HIV (Human Immunodeficiency Virus), HIV therapy, Virus

≈ Comments Off on What is the current state of the HIV cure?

Tags

antiretroviral therapy (ART), Disulfiram, Latency-reversing Agents (LRA), Mississippi baby, Panobinostat, Romidepsin, The Berlin Patient, Timothy Ray Brown, Valproate, Vedolizumab, Virus latency, Vorinostat

Recent Documented Cases Of HIV Cure And Near Misses

  • As of 2016, there is one confirmed case of HIV cure, that of Timothy Ray Brown – Wikipedia, one of two The Berlin Patient – Wikipedia. Diagnosed with HIV in 1995 while studying in Berlin, Germany, in 2007 he underwent Hematopoietic stem cell transplantation – Wikipedia from a donor with a rare CCR5 – Wikipedia homozygous delta32 mutation, homozygous meaning in both alleles (1, 2). The CCR5-delta 32 mutation renders a person resistant to HIV infection by disabling its entry into susceptible cells that express CCR5 on their cell surface. Timothy Ray Brown is considered completely cured, sterile cure as in no longer harboring HIV in his body. He is off of antiretroviral therapy (ART), Management of HIV/AIDS – Wikipedia.
  • Two Boston patients were also treated using stem cell transplantation though not from CCR5-delta32 homozygous donors. However, they experienced relapse (3).
  • The VISCONTI cohort is a group of 14 French patients who started ART within the first few weeks of getting HIV infected (4). In remission now for 12 years and counting, they’re considered ‘functionally’ cured of HIV, i.e., continuing to harbor HIV but no longer needing to take ART. The same group’s also reported similar outcome for a perinatally infected case treated from birth for at least the first 5 years. This patient remained in remission when re-examined at length at 18 years of age (5).
  • The Mississippi baby – Wikipedia is a case diagnosed as HIV positive at birth and treated with powerful ART starting from the first hours of life. However, s/he suffered a relapse in 2014 (6), this after ART for the 1st 18 months followed by a full 27 months of remission.

Clearly, HIV’s ability to become latent, Virus latency – Wikipedia, is a challenge both for effective anti-HIV immunity and for accurate assessments of disease status. In such a situation a person may appear aviremic, i.e., no virus detected in circulation, and yet have sufficient virus within latently infected cells to trigger relapse.

Main Obstacle To HIV Cure: Virus latency – Wikipedia

CD4 T cells (T helper cell – Wikipedia) and other Myeloid – Wikipedia, i.e., bone-marrow-derived, cells are the main targets of HIV infection. Problem is replication-competent HIV provirus can persist in resting CD4 T cells and maybe in these other cells as well. In other words, virus latency.

Accurately assess latent virus load, reverse it and help sustain effective anti-HIV immunity to completely eradicate HIV, these are the key steps necessary to mediate ‘cure’ in HIV patients on ART.

To devise a cure in those on ART, an accurate measure of virus load is key. However, it’s technically difficult to do so.

  • Methods that measure integrated HIV virus DNA tend to overestimate latency since they can’t discriminate replication-defective HIV DNA (7).
  • Similar drawback attends methods that measure HIV RNA (8).
  • While the quantitative viral outgrowth assay (QVOA) is far better at measuring frequency of truly latent, replication-competent provirus (9, 10), it tends to underestimate the size of the latent reservoir (8).

Latency-reversing Agents (LRA) such as Disulfiram – Wikipedia, Panobinostat – Wikipedia, Romidepsin – Wikipedia, Valproate – Wikipedia, and Vorinostat – Wikipedia interfere with latency process. However, several technical challenges in accurately assessing their capacity to inhibit and/or reverse latency include

  • Data that suggests each one may reverse latency in only a subset of HIV-infected cells.
  • How accurately do data from animal models or in vitro studies recapitulate the situation in human patients?

Such doubts suggest combinations of LRAs may be needed to fully reverse latency. Obviously, if latency’s successfully reversed, anti-HIV immunity needs to kick in to completely eliminate the virus.

  • However, is that possible for HIV patients on ART?
  • Virus may persist as latent provirus in rare cells widely distributed within the body. How often does virus replicate under these conditions and does such replication engender sufficient antigen expression and presentation to trigger an effective immune response?
  • Were such reactivation even to occur, wouldn’t anti-HIV immunity have waned in the meantime?
  • Couldn’t such immunity also be depleted and/or dysfunctional as a result of HIV infection anyway? For e.g., latent virus sequestered within resting CD4 T cells does contain some CD8 T cell escape mutations (11), an important escape mechanism since CD8 T cells (Cytotoxic T cell – Wikipedia) are among the most effective in killing virus-infected cells.
  • Those on ART tend to have low frequencies of HIV-specific CD8 T cells (12). This means there’s a need to support efficient anti-HIV immunity in such patients through the use of therapeutic vaccines. However, none are as yet available. Two major obstacles they face
    • To work even in the presence of ART. After all, to stop ART would be too risky.
    • Identify epitopes relevant during latency reversal.

A recent surprising study was a monkey study that showed ‘cure’ using Vedolizumab – Wikipedia, a monoclonal antibody (mAb) against a gut-specific cell-surface receptor, a4b7 (13, 14). However, at this stage, this is really preliminary data. Has to be replicated by other groups then tested in humans. Another caveat as well, namely, it used not HIV but rather SIV, Simian immunodeficiency virus – Wikipedia.

Thus, current path to HIV cure is far from straightforward. However, cases such as the Berlin patient and the VISCONTI cohort have at least cure put on the map, something that wasn’t even a consideration until fairly recently.

Bibliography

1. Hütter, Gero, et al. “Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation.” New England Journal of Medicine 360.7 (2009): 692-698. http://www.nejm.org/doi/pdf/10.1…

2. Yukl, Steven A., et al. “Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient.” PLoS Pathog 9.5 (2013): e1003347. http://journals.plos.org/plospat…

3. Henrich, Timothy J., et al. “Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases.” Annals of internal medicine 161.5 (2014): 319-327. https://www.researchgate.net/pro…

4. Sáez-Cirión, Asier, et al. “Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study.” PLoS Pathog 9.3 (2013): e1003211. http://journals.plos.org/plospat…

5. Frange, Pierre, et al. “HIV-1 virological remission lasting more than 12 years after interruption of early antiretroviral therapy in a perinatally infected teenager enrolled in the French ANRS EPF-CO10 paediatric cohort: a case report.” The Lancet HIV 3.1 (2016): e49-e54. http://www.natap.org/2015/HIV/PI…

6. Luzuriaga, Katherine, et al. “Viremic relapse after HIV-1 remission in a perinatally infected child.” New England Journal of Medicine 372.8 (2015): 786-788. http://www.nejm.org/doi/pdf/10.1…

7. Eriksson, Susanne, et al. “Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies.” PLoS Pathog 9.2 (2013): e1003174. http://journals.plos.org/plospat…

8. Ho, Ya-Chi, et al. “Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure.” Cell 155.3 (2013): 540-551. http://www.cell.com/cell/pdf/S00…

9. Siliciano, Janet D., et al. “Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells.” Nature medicine 9.6 (2003): 727-728.

10. Crooks, Amanda M., et al. “Precise quantitation of the latent HIV-1 reservoir: implications for eradication strategies.” Journal of Infectious Diseases 212.9 (2015): 1361-1365. Implications for Eradication Strategies

11. Deng, Kai, et al. “Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations.” Nature 517.7534 (2015): 381-385. https://www.researchgate.net/pro…

12. Shan, Liang, et al. “Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation.” Immunity 36.3 (2012): 491-501. http://www.cell.com/immunity/pdf…

13. Byrareddy, Siddappa N., et al. “Sustained virologic control in SIV+ macaques after antiretroviral and α4β7 antibody therapy.” Science 354.6309 (2016): 197-202.

14. Cohen, Jon. “Surprising treatment ‘cures’ monkey HIV infection.” (2016): 157-158.

Further reading

Margolis, David M., et al. “Latency reversal and viral clearance to cure HIV-1.” Science 353.6297 (2016): aaf6517.

https://www.quora.com/What-is-the-current-state-of-the-HIV-cure/answer/Tirumalai-Kamala

Advertisements

Share this:

  • Twitter
  • Facebook
  • Google
  • LinkedIn

Like this:

Like Loading...
Tirumalai Kamala

Tirumalai Kamala

A Ph.D. in Microbiology from India. Immunology training and research at the NIH, USA. Science is not just a career, rather it's my vocation. My specific interests: 1. Our immune responses. How do they start? Continue? Stop? 2. Science as an enterprise. The boons and banes. Why we do what we do. How do we do it? This blog re-posts my Quora answers. Its purpose is to demystify science and to share snippets of insights I've gained in my journey thus far in both life and science.

View Full Profile →

April 2018
M T W T F S S
« Mar    
 1
2345678
9101112131415
16171819202122
23242526272829
30  

Archives

  • April 2018 (6)
  • March 2018 (8)
  • February 2018 (8)
  • January 2018 (9)
  • December 2017 (9)
  • November 2017 (9)
  • October 2017 (9)
  • September 2017 (8)
  • August 2017 (9)
  • July 2017 (9)
  • June 2017 (8)
  • May 2017 (9)
  • April 2017 (9)
  • March 2017 (8)
  • February 2017 (8)
  • January 2017 (9)
  • December 2016 (8)
  • November 2016 (9)
  • October 2016 (9)
  • September 2016 (21)
  • August 2016 (10)
  • July 2016 (8)
  • June 2016 (9)
  • May 2016 (9)
  • April 2016 (8)
  • March 2016 (9)
  • February 2016 (8)
  • January 2016 (9)
  • December 2015 (9)
  • November 2015 (9)
  • October 2015 (10)
  • September 2015 (9)
  • August 2015 (9)
  • July 2015 (9)
  • June 2015 (8)
  • May 2015 (9)
  • April 2015 (10)
  • March 2015 (9)
  • February 2015 (8)
  • January 2015 (17)
  • December 2014 (14)

Blogroll

  • My LinkedIn Profile
  • My Quora Profile
  • niaIDEAList's Report
  • NIHilist's Immunology

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 86 other followers

Follow TK Talk on WordPress.com

Category

Academia Allergic hypersensitivity Allergy Anti-viral Antibiotics Antibodies Asthma Atopic dermatitis Atopy Autism Autoimmunity Bacteria B cells BCG Vaccine Biology Biomedical research Biomedicine Biotechnology Blood Brain Cancer Cancer Therapeutics CD4 helper T cells CD8 T cells Cell lines Clinical trials Clostridium difficile CNS (Central Nervous System) Diagnostics Diet Eczema (atopic dermatitis) Epidemiology Epigenetics Evolution FDA Fecal Microbiota Transplant Fever Fungi Gut microbiota Hepatitis B Hepatitis C HIV (Human Immunodeficiency Virus) Human Human Gut Microbiota Hygiene Hypothesis Hypothesis Immune dysregulation Immune Responses Immune System Immune Tolerance Immunity Immunologic Adjuvant Immunological Memory Immunology Immunotherapy India Infection Infectious disease Infectious diseases Inflammation Influenza Informed Consent Life Major Histocompatibility Molecule (MHC) Malaria Medicine Microbe Microbiology Microbiome Microbiota Mosquito Mosquito-borne diseases Mouse MS (Multiple Sclerosis) Obesity Pathogens Philosophy Placebos Psychology RA (Rheumatoid Arthritis) Rabies Science Scientific data Scientific Method Scientific Publication Scientific Research Skin Start-up Statistics T cells Technology Tuberculosis (TB) Tumor Tumor-specific antigens Vaccination Route Vaccines Vector-borne diseases Virus WHO Zika

Tags

Academic Journals Academic Publishing Academic Research Adjuvants Albert Calmette ALL (Acute Lymphoblastic Leukemia) Antibody isotype Barry Marshall B cell development Blood test Breast-feeding Cancer Immunotherapy CAR (Chimeric Antigen Receptor)-T Charles Janeway Checkpoint inhibitors Ciprofloxacin Clemens von Pirquet Cold Coley's toxins Correlates of Protection Cross-reactivity Cytokines DTaP (Diphtheria-Tetanus-acellular Pertussis) Edward Tufte Elizabeth Holmes Fabrizio Benedetti Flavivirus Gastrointestinal (GI) tract Graphpad Prism Guido Majno Guinea pig Helicobacter pylori HIV Human Papilloma virus Immune responses Intravenous Isabelle Joris John Carreyrou Lactobacillus Lactobacillus plantarum Lactobacillus rhamnosus Lineage Margaret McFall-Ngai Marginal zone B cells Measles Meta-analysis Monoclonal antibody (mAb) Mycobacterium tuberculosis Newborn NK (natural killer) cell Passive Immunity Paul W. Ewald Ph. D. Placenta Plasmodium Primordial life Psychoneuroimmunology Publication bias Rhinovirus Robert Koch Silicon Valley Smallpox Streptococcus pneumoniae Ted Kaptchuk Theranos Tissue Transplant Transplantation Tumor-Infiltrating Lymphocytes (TIL) Vaginal Microbiota Vagus nerve Vision Vitamin D William Coley Yellow Fever
  • RSS - Posts
  • RSS - Comments
Advertisements

Create a free website or blog at WordPress.com.

%d bloggers like this: